We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Notice for burosumab (Kyowa Kirin Australia Pty Ltd)
Active ingredients
burosumab
Sponsor
Date of review outcome
Lapse date
Type
Priority review
Indication
for the treatment of X-linked hypophosphataemia in adult and paediatric patients 1 year of age or older
Therapeutic area
Endocrinology